Gilead stock surged to a buy zone Wednesday after the company obliterated fourth-quarter forecasts and issued an upbeat ...

A change in Medicare policy is expected to flatten revenue from Gilead Science's HIV products, one of its most profitable segments.

Shares of Gilead Sciences ( GILD 7.46%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big ...

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and provided 2025 earnings per share guidance that came in above analysts ...

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Recent health news highlights include Gilead's upbeat 2025 forecast, Edwards Lifesciences surpassing profit estimates, New ...

Gilead Sciences posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst ...